Aimed at strengthening regulatory oversight of advanced and emerging medical technologies, the Central government has amended the Drugs Rules, 1945 to bring stem cell derived products, gene therapeutic products, and xenografts under the ambit of the Centrally Licence Approving Authority (CLAA) framework.
Under the Drugs and Cosmetics Act, certain specified categories of critical drugs and biological products are under the joint regulatory supervision of the Central and State regulators. These include vaccines, large volume parenterals (IV solutions > 100 ml) and r-DNA based medicines. This set is being expanded with this amendment to cover additional emerging technologies, said a release issued by the Ministry on Thursday (July 2, 2026).
Cell or stem cell-derived products such as stem cell-based regenerative treatments and CAR-T cell therapies have seen increasing use in treatment of blood cancers such as leukemias and lymphomas.
Gene therapeutic products such as gene replacement and gene-editing products have found use in treating genetic disorders and various types of cancers. Xenografts are animal tissue-derived products such as heart valves which can be transplanted into humans. These have use in cardiology and orthopedics.
CAR T-cell therapy and its promise of new hope for cancer treatment
Since these technologies represent highly complex, specialised and rapidly evolving areas of medical science, they need enhanced regulatory scrutiny to ensure patient safety, the Ministry added.
‘’The inclusion of these products under the CLAA framework will facilitate a system of joint oversight by the Central and State Licensing Authorities, thereby ensuring uniformity in regulatory standards across the country. The amendment will increase regulatory rigour for emerging technologies and reinforcing India’s regulatory framework in line with scientific advancements and global best practices,’’ the Ministry said in its statement.
Published – July 02, 2026 11:33 pm IST
